49
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Dose Intensification of Etoposide in the BEAM ABMT Protocol for Malignant Lymphoma

, , &
Pages 263-270 | Received 30 Jun 1994, Published online: 01 Jul 2009

References

  • Linch D. C., Winfield D., Goldstone A. H., et al. Dose intensification is effective in relapsed or resistant Hodgkin's Disease: Results of the BNLI randomised study. Lancet. 1993; 341: 138–142
  • Chopra R., Linch D. C., McMillan A. K., et al. MiniBEAM plus BEAM ABMT as salvage treatment for very poor prognosis Hodgkin's Disease. Br. J. Haem. 1991; 77(Suppl 1)20
  • Pusey W. A. Cases of sarcoma and of Hodgkin's disease treated by exposure to X rays: A preliminary report. JAMA 1902; 38: 166
  • Kaplan H. S. Hodgkin's disease Biology, treatment and prognosis. Blood 1981; 57: 813
  • De Vila V. T., Simon R. M., Hubbard S. M., et al. Curability of advanced Hodgkin's Disease with chemotherapy: Long term follow up of MOPP treated patients at the NCI. Ann. Intern. Med. 1980; 92: 587–595
  • De Vita V. T., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin' s disease. Ann. Intern. Med 1970; 78: 881
  • Longo D. L., Young R. C., Wesley M., et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 1295
  • Klimo P., Connors J. M. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABVD hybrid program. Sent, in Haematol. 1988; 25: 34
  • Cannellos G. P., Anderson J. R., Propert K. J., et al. Chemotherapy of advanced Hodgkin's Disease with MOPP, ABVD or MOPP alternating with ABVD. N. Eng. J. Med. 1992; 327: 1478–1484
  • Goldstone A. H., Linch D. C. Bone marrow transplantation in the malignant lymphomas. Recent Advances in Haematology, A. V. Hoffbrand, M. K. Brenner. Churchill Livingstone. 1992
  • Tannir N., Hagemeister F., Velasques W., et al. Longterm followup with ABDIC salvage chemotherapy of MOPP resistant Hodgkin's disease. J. Clin. Oncol. 1983; 1: 432
  • Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP resistant Hodgkin's disease. Ann. Intern. Med. 1982; 96: 139
  • Longo D. L., Duffey P. L., Young R. C., et al. Conventional dose salvage chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J. Clin. Oncol. 1991; 10: 210
  • Viviani S., Santoro A., Negretti E., et al. Salvage chemotherapy in Hodgkin's disease. Ann. Oncol. 1990; 1: 123
  • Gore M. E., McElwain T. J. Lymphomas: the impact of chemotherapy on survival. Cancer Surv. 1989; 8(3)647–670
  • Weick J., Dahlberg S., Miller T., et al. The treatment of Non Hodgkin's lymphoma with m-BACOD, ProMACE-CytaBOM and MACOP-B: The Southwest Oncology Group (SWOG) Experience. Proceedings of ASCO, San Francisco, 1989; 254, 8, Abstract 990
  • Vose J. M., Armitage J. O. The present status of therapy for patients with aggressive Non Hodgkin's Lymphoma. Ann. Oncol. 1991; 2(suppl 2)171–176
  • Armitage J. O. Drug therapy: Treatment of Non Hodgkin's Lymphoma. New. Engl. J. Med. 1993; 328(14): 1023–1030
  • Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced nonhodgkin's lymphoma. N. Eng. J. Med. 1993; 328: 1002–1006
  • Jones J. M. Advances in the treatment of Non Hodgkin's Lymphoma. J. Med. Assoc. Ga. 1989; 78(2)105–108
  • Soiffer R. J., Caliguiri M. A., Tondini C., Canellos G. P. High dose cytosine in relapsed and refractory Non Hodgkin's Lymphoma: limited role as a single agent. Cancer 1989; 74(7)2579–2584, 15
  • De Lord C., Newland A. C., Linch D. C., Vaughan-Hudson B., Vaughan-Hudson G. Failure of IM VP16 as second line treatment for relapsed or refractory high grade Non Hodgkin's Lymphoma. Haemal. Oncol. 1992; 10: 81–86
  • Velasquez W. S., Cabinills P., Salvador P. Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP). Blood 1988; 71: 117–122
  • Cabinillas F. Experience with ifosphamide combinations in malignant lymphomas. Sent. Oncol. 1989; 16(1)78–81
  • Armitage J. O., Vose J. M., Bierman P. J. Salvage therapy for patients with Non Hodgkin's Lymphoma. Monogr Natl Cancer Inst. 1990; 10: 39–43
  • Goldie J. H., Coldman A. J. A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treatment Reports 1979; 63: 1727–1733
  • Skipper H. E. Criteria associated with the destruction of leukaemia and solid tumor cells in animals. Cancer Res. 1967; 27(1)2636–2645
  • Hryniuk W. M. The importance of dose intensity on the outcome of chemotherapy. Important Advances in Oncology, V. T. De Vita, S. Hellman, S. A. Rosenberg. J. B. Lippencott, Philadelphia 1990; 121–142
  • Lepage E., Gisselbrecht C., Haioun C., Sebban C., Bosly A., Tilly H., Morel P., Herbrecht R., Reyes F., Coiffier B. Relative received dose intensity in poor risk lymphoma patients: higher Dl correlates with longer survival. Blood 1992; 80(10)158, suppl 1
  • Gribben J. G., Vaughan-Hudson B., Linch D. C. The potential value of therapy with autologous bone marrow rescue in the treatment of the malignant lymphomas. Haematol. Oncol. 1987; 5: 281–286
  • Phillips G. L., Wolf S. N., Herzig R. H., et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086
  • Peterson F. B., Appelbaum F. R., Hill R., et al. Autologous bone marrow transplantation for malignant lymphoma: A report of one hundred and one cases from Seattle. J. Clin. Oncol. 1990; 8: 638
  • McMillan A. K., Goldstone A. H., Linch D. C. One hundred cases of relapsed Hodgkin's disease treated with BEAM chemotherapy in a single centre. Proceedings of the Fourth International Conference on Malignant Lymphomas. 1990; 22
  • Jones R. J., Piantadosi S., Mann R. B., et al. High dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's Disease. J. Clin. Oncol 1990; 8: 527–537
  • Phillip T., Hartman O., Biron P., Cahn J. Y., Pein F., Bordigoni P., Soullet G., Gartner M., Lasset C., Chauvin F. High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy fordiffuse Non Hodgkin's Lymphoma. J. Clin. Oncol. 1988; 6(7)1118–1124
  • Freedman A. S., Takvorian T., Anderson K. C., Mauch P., Rabinowe S. N., Blake K., et al. Autologous bone marrow transplantation in B-cell Non Hodgkin's Lymphoma: very low treatment related mortality in 100 patients in sensitive relapse. J. Clin. Oncol 1990; 8(5)784–791
  • Coser P., Santini G., Rizzoli V., Porcellini A., Chisesi T., Sertoli R., Contu A., et al. Autologous bone marrow transplantation (ABMT) in poor prognosis diffuse Non Hodgkin's Lymphoma: Report of the Non Hodgkin's Lymphoma Cooperative Study Group. Bone Marrow Transplant. 1989; 4(suppl 4)164–175
  • Armitage J. O. Autologous bone marrow transplantation for patients with aggressive Non Hodgkin's Lymphoma. Bone Marrow Transplant. 1992; 10(suppl 1)62–63
  • Vose J. M., Armitage J. O., Bierman P. J., Weisenberger D. D., Hitchins M., Dowling M. D., et al. Salvage therapy for relapsed or refractory Non Hodgkin's Lymphoma utilising autologous bone marrow transplantation. Am. J. Med. 1989; 87(3)285–288
  • Tura S., Zinzani P. L., Mazza P., Boccia M., Gherlinzoni F., Pileri S., Amadori S., et al. ABMT vs DHAP in residual disease following third generation regimens for aggressive Non Hodgkin's Lymphomas. Blood 1992; 80(10)157, suppl 1
  • Gianni A. M., Bregni S., Sienna S., Brambilla C., Lombardi F., Gandola C., Tarella A., Stern P., Valagussa P., Bonnadonna G. Prospective randomised study of MACOP-B vs rhGM-CSF supported high dose sequential myeloablative chemoradiotherapy in diffuse large cell lymphomas. Proceedings of ASCO 1991; 10: 274, (abstr)
  • Wheeler C., Antin J. H., Churchill W. H., et al. Cyclophosphamide, carmustine and etoposide with ABMT in refractory Hodgkin's disease and Non Hodgkin's Lymphoma: A dose finding study. J. Clin. Oncol 1990; 8: 648
  • Zulian G. B., Selby P., Milan S. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br. J. Cancer 1989; 59: 631
  • Phillips G. L., Shepard J. D., Barnett M. J., Lansdorp P. M., Klingeman H. C., Spinelli J. J., Nevill T. J., Chan K. W., Reece D. E. Busulphan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in haematolog-ical malignancy. J. Clin. Oncol 1991; 9(10)1880–1888
  • Bearman S. I., Applebaum F. R., Buckner C. D., Petersen F. B., Fisher L. B., et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol 1988; 6: 1562–1568
  • Cowen D., Richaud P., Marit G., Cony-Makhoul P., Trouette R., Faberes C., Reiffers J. Regimen related toxicity in patients undergoing bone marrow transplantation with total body irradiation using a sweeping beam technique. Bone Marrow Transplant. 1992; 10: 515–519
  • Carella A. M., Carlier P., Congui A., et al. Autologous bone marrow transplantation as an adjuvant therapy of high risk Hodgkin's disease patients in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant. 1991; 8: 31–35
  • Jaganath S., Armitage J. O., Dicke K. A., et al. Prognostic indicators after high dose cyclophoshamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's Disease. J. Clin. Oncol 1989; 7: 179–185
  • Khwaja A., Mills W., Leveridge K., et al. Efficacy of delayed Granulocyte colony stimulating factor after autologous bone marrow transplantation. Bone Marrow Transplant. 1993; 11: 479–482
  • Goldstone A. H., Kwaja A. K. The role of haematopoeitic growth factors in bone marrow transplantation. Leuk. Res. 1990; 14: 721
  • Sheridan W. P., Morstyn G., Wolf, et al. Granulocyte colony stinulating factor and recovery after high dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895
  • Gribben J. G., Linch D. C., Goldstone A. H., et al. High dose chemotherapy and ABMT in NHL is successful only in those patients who have disease that is responsive to conventional dose therapy. J. Clin. Oncol 1989; 7: 1621–1629

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.